601. Synthesis, identification and in vivo studies of tumor-targeting agent peptide doxorubicin (PDOX) to treat peritoneal carcinomatosis of gastric cancer with similar efficacy but reduced toxicity
- Author
-
Raymond A Firestone, Ji-guo Li, Li Tang, Yan-chao Xin, Ya-Ping Hong, Rui Duan, Han-lin Wu, Yan-Jun Zhong, and Yan Li
- Subjects
Male ,Cancer Research ,Pharmacology ,Cathepsin B ,Stomach Neoplasms ,In vivo ,Carcinoma ,medicine ,Animals ,Prodrugs ,Cytoreductive surgery ,Platelet ,Doxorubicin ,Peritoneal Neoplasms ,Peptide doxorubicin ,business.industry ,Research ,Cancer ,Prodrug ,medicine.disease ,Disease Models, Animal ,Hyperthermic intraperitoneal chemotherapy ,Oncology ,Molecular Medicine ,Rabbits ,Gastric cancer ,business ,Oligopeptides ,Peritoneal carcinomatosis ,medicine.drug - Abstract
Background: This work aimed to synthesize a cathepsin B (CTSB)-cleavable tumor-targeting prodrug peptide doxorubicin (PDOX) and study the in vivo efficacy and toxicities on an animal model of gastric peritoneal carcinomatosis (PC). Methods: PDOX was synthesized using doxorubicin (DOX) attaching to a CTSB-cleavable dipeptide Ac-Phe-Lys and a para-amino-benzyloxycarbonyl (PABC) spacer. PC model was established by injecting VX2 tumor cells into the gastric sub-mucosa of 40 rabbits, which then were randomized into 4 groups: the Control (n = 10) without treatment, the HIPEC (n = 10) receiving cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC), the PDOX (n = 10) and the DOX (n = 10) receiving systemic chemotherapy with PDOX 50.0 mg/kg or DOX 5.0 mg/kg, respectively, after CRS + HIPEC. Results: The median overall survivals (OS) were 23.0 d (95% CI: 19.9 d - 26.1 d) in the Control, 41.0 d (36.9 d - 45.1 d) in the HIPEC, 65.0 d( 44.1 d-7 1.9 d) in the PDOX, and 58.0 d( 39.6 d-5 4.4 d) in the DOX. Compared with the Control, the OS was extended by 70% in the HIPEC (p < 0.001) and further extended by 40% in the DOX (p = 0.029) and by 58% in the PDOX ( p= 0.021), and the PC severity was decreased in the HIPEC and further decreased in the PDOX and DOX. Animals receiving DOX treatment showed hematological toxicities with marked reduction of white blood cells and platelets, as well as cardiac toxicities with significant increases in creatine kinase mb isoenzyme, evident myocardium coagulation necrosis, significant nuclear degeneration, peri-nucleus mitochondria deletion, mitochondria-pyknosis, and abnormal intercalated discs. But these toxicities were not evident in the PDOX. Conclusions: PDOX is a newly synthesized tumor-targeting prodrug of DOX. Compared with DOX, PDOX has similar efficacy but reduced hematological and cardiac toxicities in treating rabbit model of gastric PC.
- Full Text
- View/download PDF